Sight Sciences, Inc.

Sight Sciences, Inc. is an eyecare technology company dedicated to developing and commercializing transformative, interventional solutions for prevalent eye diseases. Incorporated in Delaware in 2010, the company's mission is to empower eyecare providers to elevate the standards of care by offering innovative technologies that address the underlying causes of chronic eye conditions. Its headquarters are located in Menlo Park, California.

The company's product portfolio is segmented into Interventional Glaucoma and Interventional Dry Eye. Key offerings in the Interventional Glaucoma segment include the OMNI Surgical System and the SION Surgical Instrument, which are minimally invasive technologies designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. For Interventional Dry Eye, Sight Sciences offers the TearCare System, an in-office device cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

Paul Badawi serves as the Founder and CEO of Sight Sciences. The company is publicly traded on the Nasdaq exchange under the ticker symbol SGHT. Recent developments include the launch of the OMNI Edge Surgical System in April 2025, an advanced technology for minimally invasive glaucoma surgery, and positive advancements in Medicare coverage for its TearCare system. Sight Sciences also secured a jury verdict and monetary damages against Alcon in a patent infringement case.

Latest updates

Sight Sciences Schedules Investor Presentations Amid Growth Scrutiny

Event summary

  • Sight Sciences will present at the BofA Securities Health Care Conference on May 13, 2026, at 3:15 PM PT.
  • The company will also participate in the Stifel Virtual Ophthalmology Forum on May 26, 2026, at 9:00 AM PT.
  • Presentations will be webcast live and archived on the company’s investor relations website.
  • Sight Sciences’ product portfolio includes the OMNI Surgical System, SION Surgical System, and TearCare System, targeting glaucoma and dry eye diseases.

The big picture

Sight Sciences’ investor presentations come as the company navigates a competitive landscape in the ophthalmology device market. The presentations offer a chance to reinforce the company’s growth narrative and address investor concerns about market penetration and profitability. The company's focus on minimally invasive glaucoma surgery and dry eye treatments positions it within a growing segment of the broader eye care market, but execution remains critical.

What we're watching

Growth Trajectory
The presentations will likely focus on the commercial adoption rates of the OMNI and TearCare systems, and any shift in sales strategy will be key to monitor.
Competitive Landscape
Given the crowded ophthalmology device market, the company’s ability to differentiate its technology and maintain pricing power will be crucial for sustained growth.
Regulatory Risk
Continued 510(k) clearance and CE marking for existing and new products will be essential for maintaining market access and expanding into new territories.
CID: 3597